Comparable social novelty scores were seen between vehicle-treated normal C57BL/6J mice and MT-II treated MIA mice, though a significant treatment interaction was not observed between the two groups
Semaglutide (GLP-1 agonist) shows efficacy for weight loss and cardiovascular risk reduction, with clinical trials demonstrating 1015% body weight reduction in select populations
Heres the part everyone is waiting for
Guo X, Xing J, Shi X, Cao Y, An L (2025) Effects of neural stem cell-derived exosomes on MPTP-induced Parkinsons disease in mice
Understanding your genetic predispositions can support a more informed conversation with your provider about treatment selection (compounded semaglutide, tirzepatide, or dual-compound options), realistic expectations, and monitoring strategy